NEW YORK – Danaher subsidiary Beckman Coulter and cell morphology firm Scopio Labs announced on Wednesday a deal to expand Scopio's digital blood smear platforms.
The deal would reduce laboratory workloads and aid image sharing, the companies said, adding Scopio's next-generation peripheral blood smear platforms use full-field imaging and AI-supported decisions to eliminate manual microscopy. The technology also helps laboratory diagnosticians and clinicians share high-resolution full-field images over hospital networks.
Financial and other terms of the partnership were not disclosed.
Scopio, which is based in Tel Aviv, Israel, received 501(k) clearance from the US Food and Drug Administration in May to market its Scopio X100HT instrument, which updates a previously cleared X100 hematology imaging device by adding an automated slide loader that allows analysis of up to 30 slides. Documents filed with the FDA indicate the device is intended to help laboratory technologists locate and display images of white and red blood cells and platelets from fixed and stained peripheral blood smears and help technologists conduct a white blood cell differential, red blood cell morphology evaluation, and platelet estimate.
The companies said the X100HT can process up to 40 samples per hour.
According to the partners, peripheral blood smear results are critical for the early diagnosis and treatment of diseases such as blood cancers, anemia, and infections. Most such tests are currently performed through manual microscopy.
Peter Soltani, senior VP and general manager at Brea, California-based Beckman Coulter, said in a statement that Scopio’s technology provides rapid high-resolution imaging, which is a "leap in digital morphology capabilities," with the potential to help laboratories reduce their manual labor and improve turnaround time.
Itai Hayut, cofounder and CEO of Scopio Labs, added that the partnership would "accelerate the digital transformation of hematology laboratories worldwide."